Medios AG Cash Flow Conversion Efficiency
Medios AG cash flow conversion efficiency. Based on the latest financial reports, Medios AG (ILM1) has a cash flow conversion efficiency ratio of 0.021x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.96 Million ≈ $12.81 Million USD) by net assets (€519.70 Million ≈ $607.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medios AG (2010–2025)
Cash flow conversion efficiency of Medios AG from 2010 to 2025. This chart illustrates how Medios AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medios AG (ILM1) share price today for real-time trading data and today's change.
Medios AG Cash Flow Conversion Ratio Explained
Medios AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medios AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medios AG ranked by their cash flow conversion efficiency. Also see ILM1 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
i3system Inc
KQ:214430
|
0.073x |
|
Wuxi Xinan Technology Co. Ltd. A
SHE:301170
|
N/A |
|
NCT Alliance Bhd
KLSE:0056
|
-0.022x |
|
KISCO Corp
KO:104700
|
0.008x |
|
Sphera Franchise Group SA MiFID Eligible Security
RO:SFG
|
0.689x |
|
China Metal Products Co Ltd
TW:1532
|
0.089x |
|
Beijing Seeyon Internet Software Cp
SHG:688369
|
-0.118x |
|
Daesung Finetec Co.Ltd
KQ:104040
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Medios AG (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medios AG from 2010 to 2025. Review Medios AG free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €514.22 Million ≈ $601.18 Million |
€43.00 Million ≈ $50.27 Million |
0.084x | -42.08% |
| 2024-12-31 | €510.19 Million ≈ $596.47 Million |
€73.67 Million ≈ $86.12 Million |
0.144x | +312.59% |
| 2023-12-31 | €468.81 Million ≈ $548.08 Million |
€16.41 Million ≈ $19.18 Million |
0.035x | -57.76% |
| 2022-12-31 | €448.05 Million ≈ $523.81 Million |
€37.12 Million ≈ $43.40 Million |
0.083x | -46.92% |
| 2021-12-31 | €394.16 Million ≈ $460.82 Million |
€61.52 Million ≈ $71.92 Million |
0.156x | +158.32% |
| 2020-12-31 | €142.43 Million ≈ $166.51 Million |
€-38.12 Million ≈ $-44.56 Million |
-0.268x | -4762.04% |
| 2019-12-31 | €81.63 Million ≈ $95.43 Million |
€-449.29K ≈ $-525.26K |
-0.006x | +87.62% |
| 2018-12-31 | €70.50 Million ≈ $82.42 Million |
€-3.14 Million ≈ $-3.67 Million |
-0.044x | -348.97% |
| 2017-12-31 | €45.68 Million ≈ $53.40 Million |
€816.00K ≈ $953.99K |
0.018x | +138.51% |
| 2016-12-31 | €34.10 Million ≈ $39.86 Million |
€-1.58 Million ≈ $-1.85 Million |
-0.046x | +84.92% |
| 2015-12-31 | €323.78K ≈ $378.53K |
€-99.64K ≈ $-116.49K |
-0.308x | -- |
| 2014-12-31 | €0.00 ≈ $0.00 |
€13.30K ≈ $15.55K |
x | -- |
| 2013-12-31 | €7.81K ≈ $9.13K |
€103.36K ≈ $120.84K |
13.241x | +10691.51% |
| 2012-12-31 | €172.97K ≈ $202.22K |
€21.22K ≈ $24.81K |
0.123x | +157.35% |
| 2011-12-31 | €376.75K ≈ $440.46K |
€-80.60K ≈ $-94.23K |
-0.214x | -1872.06% |
| 2010-12-31 | €341.07K ≈ $398.75K |
€-3.70K ≈ $-4.33K |
-0.011x | -- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more